Vectura Group

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Vectura Group plc
Public (LSEVEC)
Industry Pharmaceuticals
Founded 1997
Headquarters Chippenham, UK
Key people
Bruno Angelici, Chairman
James Ward-Lilley, (CEO)
Revenue £72.0 million (2016)[1]
£(5.1) million (2016)[1]
£5.0 million (2016)[1]

Vectura Group plc (LSEVEC) is a British-based pharmaceuticals business. It is based in Chippenham and is a constituent of the FTSE 250 Index.


The company was formed in 1997 as a start-up pharmaceuticals business.[2] In 1999 it acquired Co-ordinated Drug Development and the Centre for Drug Formulation Studies.[2] In 2004 it was listed on the Alternative Investment Market.[2] In 2007 it acquired Innovata plc, another developer of pulmonary products,[3] and then moved on the full list of the London Stock Exchange.[2] It acquired Activaero, a German manufacturer in the same sector, for £108 million in March 2014.[4] On 10 June 2016 Vectura completed a merger with Skyepharma; the merged company will continue to be known as Vectura.[5]


The Group is a developer of inhaled therapies for the treatment of respiratory diseases.[6]


  1. ^ a b c "Annual Report 2015/16" (PDF). Vectura Group. Retrieved 24 November 2016. 
  2. ^ a b c d "History". Vectura Group. Retrieved 3 August 2016. 
  3. ^ Vectura buys Innovata Guardian, 17 November 2006
  4. ^ "UK's Vectura buys Activaero for £108 million". Pharma Times. 16 March 2014. Retrieved 20 June 2015. 
  5. ^ "Vectura and Skyepharma to merge in £441m deal". The Telegraph. 16 March 2016. Retrieved 11 June 2016. 
  6. ^ "Dr Karl Keegan to join Vectura Group". Manufacturing chemist. Retrieved 20 June 2015. 

External links[edit]